Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_2
2
67%
Ph phase_1
1
33%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(2)
Terminated(1)

Detailed Status

Completed2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (33.3%)
Phase 22 (66.7%)

Trials by Status

completed267%
terminated133%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_1

Efficacy and Safety Study of Soluble Beta-1,3/1,6-Glucan in Thermal Burns

NCT00283426
completedphase_2

The Protective Effect of Soluble Beta-1,3/1,6-Glucan Compared to Placebo in Oral Mucositis in Head and Neck Cancer Patients

NCT00289003
completedphase_2

Efficacy of Soluble Beta-1,3/1,6-Glucan Compared to Placebo on Chronic Leg Ulcers in Diabetes Patients

NCT00288392

Clinical Trials (3)

Showing 3 of 3 trials
NCT00283426Phase 1

Efficacy and Safety Study of Soluble Beta-1,3/1,6-Glucan in Thermal Burns

Terminated
NCT00289003Phase 2

The Protective Effect of Soluble Beta-1,3/1,6-Glucan Compared to Placebo in Oral Mucositis in Head and Neck Cancer Patients

Completed
NCT00288392Phase 2

Efficacy of Soluble Beta-1,3/1,6-Glucan Compared to Placebo on Chronic Leg Ulcers in Diabetes Patients

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3